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Abstract
Decay-accelerating factor (CD55) is a member of
membrane-bound complement-regulatory proteins.
CD55 expression correlates with poor survival in pa-
tients with colorectal cancer and has been implicated in
the survival and tumorigenesis of blood-borne malig-
nancies. Histologic analysis of clinical specimens from
patients with advanced prostate cancer revealed an in-
crease in CD55 expression in prostate tumor epithelial
cells. CD55 was shown to be functionally active and to
inhibit complement-mediated lysis in PC-3 and DU145
cells. The percentage of lysis was correlative with the
CD55 expression profile observed in these prostate
cancer cell lines. These data suggest that CD55 is an
important regulator of prostate cancer cell survival. As
a result, we have hypothesized that CD55 expression on
prostate cancer cells promotes cell survival and con-
tributes to the metastatic potential of prostate cancer
cells. To determine the role of CD55 in prostate cancer
tumorigenesis and metastasis, we generated PC-3Luc
prostate cancer cells with CD55 siRNA-targeted disrup-
tion. We found that PC-3Luc/CD55 siRNA constructs in
SCID mice resulted in a significant attenuation of over-
all tumor burden. Further investigation into the mecha-
nisms of CD55-mediated tumor cell/microenvironment
interaction is necessary to understand the role of CD55
in tumor cell survival and metastatic lesion formation.
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Introduction
Tumorigenesis and metastasis are results of a multistep
process that begins with the transformation of cells to an on-
cogenic phenotype and includes unregulated growth, angio-
genesis, breakdown of the extracellular milieu, intravasation,
survival in the circulation, adhesion to the target organ endo-
thelium, extravasation, and subsequent growth [1,2]. Each
step in this process requires successful immune evasion by
disseminated tumor cells in an environment where there are
elevated innate immune response and elevated adaptive
immune response. The principle of immunologic surveillance
suggests that the immune system is constantly monitoring
and trying to eradicate abnormal clones recognized by the
host immune system as ‘‘foreign’’ bodies. Coley [3] demon-
strated evidence for an immune response to tumor cells by
reporting spontaneous tumor regression that is associated with
bacterial infection. Furthermore, Coley [3] noted a higher inci-
dence of spontaneous tumor development in mice with B-cell
or T-cell deficiency and reported that the presence of lym-
phocytic infiltration in tumors correlates with better prognosis.
Historically, cancer patients are known to have elevated circu-
lating tumor-specific CD8+ lymphocytes; recently, we reported
an elevation in complement activation in patients with advanced
hormone-refractory prostate cancer [4]. Antitumor immunother-
apy has demonstrated varying clinical utilities by using tumor
vaccines that target tumor-specific antigens (TSAs) and tumor-
associated antigens (TAAs) [5–9]. The expression of TSAs and
TAAs has been shown to induce the activation of the com-
plement immune system, creating a cytotoxic environment for
tumor cell metastasis [10]. The mechanisms adapted by tumor
cells that confer resistance to lysis through the homologous
complement system may identify novel potential targets for
directed therapy.
The complement immune system consists of a series of
glycoproteins that participate in an enzymatic cascade, result-
ing in the formation of membrane attack complex and cell lysis.
As a means of host protection against the ‘‘bystander killing’’
effect of activated complements, host cells expressmembrane-
bound complement-regulatory proteins (mCRPs), including a
membrane cofactor protein (CD46), a decay-accelerating factor
(CD55), and protectin (CD59), all of which inhibit complement-
mediated lysis through independent mechanisms [11–13]. Re-
cently, we have demonstrated the overexpression of CD55 in
clinical specimens from patients with advanced prostate cancer
compared to normal nonmalignant prostate tissues by tissue
microarray analysis and real-time polymerase chain reaction
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(PCR) [14]. CD55 is a glycosylphosphatidylinositol-linked
glycoprotein consisting of four SUSHI (SCR) domains in the
N-terminal domain and inhibits complement lysis by acceler-
ating the decay of C3 and C5 convertases [15]. An alternative
function of CD55 has been proposed when CD55 was
identified as a ligand for CD97 and was shown to participate
in cell-to-cell/matrix adhesion [16]. CD97 is a member of the
epidermal growth factor (EGF)-TM7 family; the binding of
CD55 to CD97 has been shown to be Ca2+-dependent and
has been implicated in the dedifferentiation of endothelial
cells [17]. In this present study, we report that prostate cancer
cells upregulate CD55 as a survival mechanism against
complement-mediated lysis. Furthermore, we provide evi-
dence to suggest a role for CD55 in prostate cancer cell
tumorigenesis and metastasis by siRNA- mediated knock-
down CD55 expression in an in vivo model of metastasis.
Materials and Methods
Materials
This studyused vascular endothelial growth factor (VEGF),
tumor necrosis factor a (TNFa), transforming growth factor b
(TGFb), EGF, interleukin (IL) 6, TRAP6 (Sigma-Aldrich, St.
Louis, MO), anti-CD55 (clone BRIC 216), rabbit complement
(Serotec, Inc., International,Raleigh,NC), anti-endoglin (clone
8E11; Chemicon International, Temecula, CA), Cy5, and calc-
ien AM (Molecular Probes, Inc., Carlsbad, CA); all other re-
agents were obtained from Sigma-Aldrich.
Cell Culture
Cell lines PC-3, DU145, LNCaP, human microvascular
endothelial cells (HMVECs), human bone marrow endothe-
lial (HBME), and RWPE-1 (ATCC, Manassas, VA) were pas-
saged under appropriate growth conditions. PC-3Luc cells
were constructed by stably transfecting PC-3 cells with lucif-
erase construct, as previously described [18]. PC-3, DU145,
and LNCaP cells were maintained in RPMI 1640 + 10% fetal
calf serum (FCS; Invitrogen Corp., Carlsbad, CA), and HBME
cells were maintained in DMEM + 10% FCS. HMVECs were
maintained in EGM + 5% FCS, and RWPE-1 cells weremain-
tained in KSFM (Invitrogen Corp.). Cells were passaged by
trypsinization using 1 trypsin + EDTA (Invitrogen Corp.) and
resuspended in appropriate growth media.
Immunoblot Analysis
Cells were lysed in RIPA buffer (50 mM Tris–HCl, pH 7.4,
1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM
Na3VO4, 1mMNaF, 1 mMokadaic acid, and 1 mg/ml aprotinin,
leupeptin, and pepstatin). Proteins were separated under
nonreducing conditions by SDS-PAGE and transferred onto
nitrocellulose membrane. Membranes were blocked with 5%
milk in TBST (0.1% Tween in TBS) for 1 hour at room tem-
perature. They were incubated overnight at 4jC with primary
antibodies: anti-CD55 (clone BRIC 216; Serotec, Inc.) and
anti-actin (Cell Signaling, Beverly, MA). Membranes were
washed three times prior to incubation with HRP-conjugated
secondary antibodies (Cell Signaling) for 1 hour at room tem-
perature. Protein expression was visualized by chemilumi-
nescence (Promega, Madison, WI).
PCR
cDNA was synthesized from 5 mg of total RNA using the
First Strand Superscript cDNA synthesis kit (Invitrogen Corp.)
following the manufacturer’s instructions. Standard PCR tech-
niques were used to detect gene expression. RNA integrity
was determined using Agilent technology prior to cDNA syn-
thesis reactions (Agilent, Inc., Palo Alto, CA). Reactions con-
tained 2.5 ml of 10 reaction buffer, 2.5 ml of 2 mM dNTP mix,
1 ml of each primer at 20 pmol/ml, 2 ml of cDNA, 0.5 ml of Taq, and
1.5 ml of 25 mMMgCl2 in a total volume of 25 ml. Gene-specific
primers were as follows: CD55 sense 5V-TGATCTGCC-
TTAAGGGCAGTCAATGGT-3V and antisense 5V-TACAATAA-
ATAGAGTGCTCTCCAATCA-3V; b-actin sense 5V-CCTCGC-
CTTTGCCGATCC-3V and antisense 5V-GGATCTTCATGA-
GGTAGTCAGTC-3V. Amplification was performed as follows:
94jC (2minutes), 94jC (30 seconds), 52jC (30 seconds), and
72jC (1 minute) at 25, 30, and 35 cycles. Amplification prod-
ucts were separated on a 1% agarose gel in 1 TBE and vi-
sualized with ethidium bromide staining. For real-time PCR
experiments, primers and probes were purchased from ABI,
Inc. Assays on Demand (Foster City, CA). GAPDH was used
as an internal control. Samples were run in replicates of
four and normalized to the respective GAPDH levels, as pre-
viously described [19].
Flow Cytometry
Cells were grown to 75% to 80% confluency and collected
by trypsinization with 1 trypsin/EDTA. Cells were washed
twicewithPBS, centrifuged, and resuspended at 5 105 cells/
ml. Primary antibodies were diluted in PBS at 1:1000 and
mixed by inversion. Primary antibodies were added to each
sample and incubated by rocking at 4jC for 1 hour. After pri-
mary incubation, PBS was added to each sample and mixed
by inversion. Samples were centrifuged, and the supernatant
was discarded. Secondary antibody (Cy-5) was added to each
sample and placed at a temperature of 4jC for 30 minutes.
After secondary antibody incubation, samples were washed
with 1 ml of PBS and centrifuged at 2000g for 5 minutes. The
supernatant was discarded, samples were resuspended in
3.7% paraformaldehyde (in PBS), and transferred to flow
cytometry tubes for analysis by the Flow Cytometry Core at
the University of Michigan (Ann Arbor, MI).
Cell-to-Cell Adhesion
HMVECs or HBME cells were plated at 5  104 cells/ml in
96-well plates and allowed to grow for 4 days at 37jC in 5%
CO2, or until they have formed 90% to 100% confluent mono-
layers. PC-3, DU145, and LNCaP cells were serum-starved
for 2 hours in SFM-RPMI and released with 0.5 mM EDTA-
HBSS for 1 hour at room temperature. PC-3, DU145, and
LNCaP were resuspended in RPMI-SFM media at 1 
106 cells/ml in PBS. PC-3, DU145, and LNCaP were labeled
with CONC calcein AM, washed with PBS, and resuspended in
SFM-RPMI with or without anti-CD55 blocking antibody at 2 
105 cells/ml. A total of 2 104 labeled PC-3, DU145, or LNCaP
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cellswere added to confluentHMVECsorHBMEcells and incu-
bated for 45minutes at 37jC in5%CO2.Cellswere then gently
washed with DPBS thrice, and absorbance was read on a mi-
crotiter plate reader at 490 nmexcitation and 530 nmemission.
Complement-Mediated Lysis Assay
Cells were plated in a 96-well plate at 5 104 cells/ml and
grown to confluence. Cells were washed twice with serum-
free RPMI 1640 + 1% bovine serum albumin (BSA) and in-
cubated with calcein AM (5 mg/ml) for 30 minutes at 37jC.
Cells were washed twice with RPMI + 1% BSA prior to op-
sonization with anti-endoglin MJ7/18 antibody (Chemicon
International) for 1 hour at 37jC. Cells were incubated in the
presence of 10% baby rabbit complement (Serotec, Inc.) in
RMPI + 1%BSA for 45minutes at 37jC. The supernatant was
transferred to a new 96-well plate and represented the
‘‘complement-mediated release’’ calceinAM fraction.Thecal-
cein AM remaining in the cells was released by incubation
with RPMI + 1% BSA + 0.1% Triton X-100 for 15 minutes at
room temperature. Lysates were then transferred to a 96-well
plate, the calcein AM was released by complement, and de-
tergent was quantified using a VersaMax (Molecular Devices,
Sunnyvale, CA) fluorescence plate reader. The percentage
of specific lysis was calculated as complement-mediated
release/maximal release multiplied by 100%, where maxi-
mal release is the complement-mediated release plus the
detergent-mediated release of calcein AM.
CD55 Deposition into the Extracellular Matrix
Cells were plated in a 96-well plate at 5 104 cells/ml and
allowed to grow for 14 hours. Cells were then stimulated with
the indicated growth factors for 24 hours in serum-freemedia.
Cells were releasedwith 0.02%EDTAat 37jC for 60minutes.
The absence of cells was confirmed by light microscopy, and
wells were washed six times with PBS. PBS + 0.05% Tween
20 was added to each well for 30 minutes at 4jC to block
nonspecific binding of antibodies. Anti-CD55 (BRIC 216) pri-
mary antibody was added to each well (10 mg/ml in PBS +
0.05%Tween 20) for 1 hour at 4jC.Wells were washed thrice
with PBS + 0.05% Tween 20, and an anti-mouse fluorescein
isothiocyanate secondary antibody was added to the wells for
1 hour at 4jC. Wells were then washed six times with PBS +
0.05% Tween 20. ABTS mixture was prepared fresh (0.2 M
dibasic sodium phosphate and 0.1 M citric acid, pH 5.0), and
30%H2O2 was added to the ABTS solution immediately prior
to use. The ABTS mixture was added to each well and read
on a microplate reader at 405 nm within 30 minutes.
CD55 siRNA Knockdown in PC-3 Cells
DNA oligos for siRNA-targeted disruption of CD55 were
designed using sequences obtained from Ambion, Inc. (Aus-
tin, TX). Sense and antisense sequences were annealed
in 1 annealing buffer and ligated into pSilencer (Ambion,
Inc.). Ligations consisting of 1 ml of annealed oligos (8 ng/ml)
and 1 ml of linearized pSilencer (0.1 mg/ml) were incubated
at 24jC for 1 hour in the presence of 5 U of T4 DNA ligase
in 1 T4 DNA ligase buffer (Invitrogen, Inc., Carlsbad, CA)
following the manufacturer’s instructions. pSilencer con-
taining GAPDH was used as control for PC-3Luc transfection,
and pSilencer containing Scrambled oligos was used as
control for siRNA-mediated knockdown.
Bioluminescent In Vivo Model of Metastasis
Bioluminescent imaging of PC-3Luc was preformed, as
previously described, through The University of Michigan
Small Animal Imaging Resource facility [18]. Briefly, PC-3Luc
cells containing CD55 siRNA or Scrambled siRNA were in-
troduced into male SCID mice (5–6 weeks) by intracardiac
injections.Micewere serially imagedweekly for 7weeks using
a charge-coupled device (CCD) IVIS system using a 50-mm
lens (Xenogen Corp., Alameda, CA), and the results were
analyzed using LivingImage software (Xenogen Corp.). Mice
were intraperitoneally injected with luciferin (40 mg/ml), and
ventral images were acquired 15 minutes postinjection under
1.75% isoflurane/air anesthesia. The total tumor burden of
each animal was calculated using regions of interest (ROIs)
that encompassed the entire animal. Animals were sacrificed
after week 7 image, and individual organswere harvested and
placed in formalin.
Histology
Animals were sacrificed, and tissue specimens were fixed
in formalin for hematoxylin and eosin histologic analysis fol-
lowing routine protocols. Tibias were decalcified in a Cal-Ex II
(Fisher Scientific, Hampton, NH) decalcifying solution for 24
to 48 hours, and 5-mm sections were placed on uncharged
glass slides. Anti-luciferase (1:3200; Sigma, St. Louis, MO)
antibodies with EnVision Rabbit Peroxidase Kit (DAKO
Corp., Carpinteria, CA) were used to confirm the presence of
PC-3Luc cells within tumors.
Statistics
Data were analyzed with GraphPad (SanDiego, CA) Prism
software. A one-way ANOVA was used with Bonferroni’s
post hoc analysis for comparisons between multiple groups.
A Student’s t test was used for comparisons between two
groups. Significance was defined as P < .05. For analysis of
in vivo bioluminescent experiments, amixed regressionmodel
was used to determine the differences in growth rate and
initial value between the CD55+ and CD55 groups. Growth
rate was explored both as a quadratic (curved) effect and
as a linear effect. Interactions were used between growth
rate and group indicator (CD55+ versus CD55) variables to
determine whether shape and rate differed by group. A back-
ward model building selection was used to arrive at the most
parsimonious model. All tests were performed at the 5% sig-
nificance level using the SAS System (SAS, Cary, NC).
Results
Previously, we have demonstrated the upregulation of CD55
expression in prostate cancer by tissue microarray analysis
[4]. To confirm the presence and overexpression of CD55
in PC-3, DU145, and LNCaP cells, CD55 expression was
determined by real-time PCR (Figure 1A) and flow cytome-
try (Figure 1, B and C) and compared to RWPE-1 cells. Flow
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cytometric analysis revealed a significant increase in the
expression of CD55 on PC-3 and DU145, but not in LNCaP
(RWPE-1: 76.88 ± 15.44; PC-3: 153.0 ± 7.49; DU145: 108.5 ±
3.18; LNCaP: 4.61 ± 3.29) (Figure 1C). To determine if
the expression of CD55 correlated with the resistance to
complement-mediated lysis, RWPE-1, PC-3, DU145, and
LNCaP cells were incubated in the presence of activated baby
rabbit complement and the percentage of lysed cells was
Figure 1. CD55 and CD97 expression in prostate cancer cell lines. (A) Real-time PCR of CD46, CD55, and CD59 in RWPE-1, PC-3, DU145, and LNCaP cell lines.
Each sample was run in quadruplicate and normalized to cell-specific GAPDH quantification. Results are expressed as fold expression of the RWPE-1 cells on a
log scale. (B) The protein expression of CD55 was performed in triplicate by flow cytometric analysis. (C) Graphic analysis of the mean fluorescent intensity was
normalized to RWPE-1 for each replicate and graphed as mean ± standard deviation. (*significance compared to RWPE-1, P < .01; #significance compared to PC-
3, P < .001). (D) Effect of CD55 expression on prostate cancer cell sensitivity to complement lysis. The sensitivity of RWPE-1, PC-3, DU145, and LNCaP cells to
complement-mediated lysis was assessed. Lysis assays were performed in triplicate, and percent lysis was calculated: (calcein AM fluorescence from the
supernatant/maximal calcein AM fluorescence)  100.
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calculated. PC-3 cells demonstrated the greatest resistance to
complement-mediated lysis, whereas LNCaP cells were the
most sensitive (PC-3: 6.045 ± 1.94; DU145: 14.30 ± 3.57;
LNCaP: 63.24 ± 3.6; HMVEC: 13.69 ± 3.53) (Figure 1D). From
these data, the expression of CD55 correlated with the sensi-
tivity of individual prostate cancer cell lines to complement-
mediated lysis and demonstrated that CD55 is present and
functional in prostate cancer cells in vitro.
Recently, a role for CD55 in adhesion to endothelial cells
has been suggested [20]; therefore, we examined the con-
tribution of CD55 in prostate cancer cell adhesion to endo-
thelial cells. PC-3, DU145, and LNCaP cells were incubated
on a confluent layer of HMVECs in the absence or presence
of an anti-CD55 blocking antibody, and the percentage of
cells that adhered was quantified. Inhibition of CD55 attenu-
ated PC-3 cell and DU145 cell adhesion to endothelial cells
(Figure 2, A and B). LNCaP cells did not adhere well to
endothelial cells, and inhibition of CD55 did not affect LNCaP
adhesion to HMVECs (Figure 2C). Previously, preferential ad-
hesion of prostate cancer cells to bone marrow endothelium
has been demonstrated [21]; therefore, we determined the
role of CD55 in PC-3 adhesion specifically to HBME cells.
Figure 2. Inhibition of CD55 attenuates PC-3 cell adhesion to endothelial cells. (A) PC-3, (B) DU145, and (C) LNCaP adhesion to HMVECs was determined in the
presence of an anti-CD55 blocking antibody. Cells were treated with anti-CD55 antibody at 5, 10, and 20 ng/ml during the 30-minute adhesion assay. (D) PC-3 cell
adhesion to HBME cells was similarly assessed. Results were normalized to untreated cells and expressed as percent adhesion above control. Analysis was
performed in triplicate, and the data are presented as mean ± standard deviation (*P < .05).
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Inhibition of CD55 attenuated PC-3 cell adhesion to HBME
cells, similar to that observed using HMVECs (Figure 2D).
CD55 has been shown to be deposited in the tumor
microenvironment and to contribute to metastasis [22,23].
Analysis of CD55 mRNA expression after growth factor
stimulation revealed an increase in CD55 mRNA expression
mediated by VEGF, TNFa, and EGF (Figure 3, A and B).
Growth factor stimulation of PC-3 cells did not alter CD55
protein expression (data not shown). Therefore, we analyzed
the ability of PC-3 to release and secrete soluble CD55
(sCD55) into the extracellularmatrix using amatrix deposition
assay. To determine the ability of PC-3 and DU145 cells to
deposit sCD55 into the extracellular matrix, cells were stimu-
lated with VEGF, TNFa, TGFb, EGF, and IL-6 for 24 hours,
and the amount of sCD55 deposited into the matrix was
quantified. PC-3 cells treated with VEGF, TNFa, and EGF
had a significant increase in the amount of sCD55 deposited
in the matrix (fold expression: VEGF: 8.787 ± 4.438; TNFa:
7.321 ± 3.407; EGF: 13.75 ± 2.555) (Figure 3C). Similarly,
DU145 cells treated with VEGF, TNFa, and EGF had a sig-
nificant increase in sCD55 deposition (fold expression: VEGF:
12.21 ± 3.938; TNFa: 13.95 ± 4.846; EGF: 16.28 ± 0.9736)
(data not shown).
To visualize the role of CD55 in prostate cancermetastasis
in an in vivo mouse model of metastasis, PC-3Luc cells were
stably transfected with siRNA constructs targeting CD55 and
decreased its expression. Three siRNA sequences targeting
distinct regions of theCD55 genewere used (CD55-1, CD55-2,
and CD55-3). We used an siRNA construct containing Scram-
bled siRNA (Scrambled) as negative control. Comparative
analysis of CD55 knockdown between independent siRNA con-
structs was confirmed by PCR analysis of CD55 expression.
Increasing amplifications revealed a decrease in CD55 expres-
sion by the CD55-3 siRNA construct compared to the GAPDH-
and CD55-1–expressing cells (Figure 4A). Decreased CD55
protein expression by CD55-3 construct was further con-
firmed by Western blot analysis (Figure 4B). Furthermore,
siRNA-mediated disruption of CD55 was shown to increase
the sensitivity of PC-3Luc cells to complement-mediated lysis
(Figure 4C). Additionally, decreased expression of CD55 did not
alter PC-3Luc cell growth in cultures (Figure 4D).
To visualize the effects of CD55 knockdown on PC-3Luc
tumor growth in an in vivo model of metastasis, male SCID
mice (5–6 weeks old) received intracardiac injections of PC-
3Luc Scrambled cells (n = 10) and PC-3Luc CD55-3 cells (n =
10), and tumor growth was monitored weekly using a CCD
camera (Figure 5A). A week 1 postinjection of all mice dem-
onstrated at least one focal point of photon emission. Serial
bioluminescent images were taken weekly for 6 weeks.
During the 6-week period, two mice with PC-3Luc Scrambled
cells and three mice with PC-3Luc CD55-3 cells expired spon-
taneously. On day 45, final images were acquired, and the
total tumor burden per animal was quantified. The total tumor
burden of mice injected with PC-3Luc CD55-3 was signifi-
cantly decreased compared to the mice injected with PC-3Luc
Scrambled cells (Scrambled: 1.29 108 ± 3.2 107; CD55-3:
3.14  107 ± 7.28  106; mean ± SEM) (Figure 5B). To con-
firm the presence of tumors, histologic sections were ana-
lyzed by hematoxylin and eosin staining and revealed tumor
infiltration in both soft tissue (data not shown) and osseous
metastasis (Figure 5, C, D and F, G). Further histologic ex-
amination of tibial lesions revealed PC-3Luc–based tumors
staining positive for luciferase (Figure 5, E and H ).
Discussion
CD55 is known to be cytoprotective against complement-
mediated lysis; however, little is known regarding the role of
Figure 3. Growth factor stimulation of PC-3 cells induces CD55 deposition.
(A) PC-3 cells were stimulated with VEGF (50 ng/ml), TNFa (50 ng/ml), BMP-2
(50 ng/ml), IL-6 (50 ng/ml), or EGF (50 ng/ml) for 24 hours. CD55 mRNA
expression was analyzed by PCR, and -actin was assessed as control. (B)
CD55 protein expression was assessed in total cell lysates by Western blot
analysis after stimulation with VEGF (50 ng/ml), TNFa (50 ng/ml), IL-6 (50 ng/
ml), or EGF (50 ng/ml) for 24 hours. (C) Soluble CD55 deposition into the
extracellular matrix was assessed in PC-3 cells treated with VEGF (50 ng/ml),
TNFa (50 ng/ml), TGF (50 ng/ml), EGF (50 ng/ml), and IL-6 (50 ng/ml) for
24 hours. Data are presented as mean ± standard deviation (*P < .01).
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CD55 in prostate cancer survival and metastasis. We have
shown that CD55 expression was significantly elevated in
PC-3 and DU145 cells, whereas LNCaP cells demonstrated
a significantly lower expression (Figure 1). Additionally, resis-
tance to complement-mediated lysis in RWPE-1, PC-3, DU145,
and LNCaP cells correlated with differential expression of
CD55, indicating a functional role in acquired resistance and
promoting prostate cancer cell survival during tumorigenesis,
circulation, and metastasis. RWPE-1 cells were used as a
reference cell line to compare the role of CD55 expression
on prostate cancer cell survival and metastasis. Sensitivity to
complement-mediated lysis correlated with increased expres-
sion of CD55 on PC-3 and DU145 cells. The fact that LNCaP
cells express extremely low levels of CD55 is unclear andmay
be a result of the cell line being derived from lymph node me-
tastasis compared to the bone and dura microenvironment for
PC-3 and DU145 cells, respectively. Future experiments
looking at the role of androgens and androgen receptor ac-
tivation in regulating CD55 expression and activity may be
important in delineating the differential expression of CD55
in various prostate cancer cell lines and clinical samples.
The regulation of CD55 expression on endothelial cells
has been shown to be a function of bFGF and VEGF stimu-
lation [24,25]. Additionally, colonic cancer cells have demon-
strated an increase in CD55 expression in response to EGF
stimulation, which is dependent on MAPK signaling [26]. To
further understand the mechanisms of CD55-regulated ex-
pression in prostate cancer, we stimulated PC-3 and DU145
Figure 4. siRNA-mediated knockdown CD55 expression in PC-3Luc cells. (A) CD55mRNA expression was visualized in PC-3Luc cells stably expressing CD55 siRNA
pSilencer constructs targeting unique regions of the CD55 gene (CD55-1 and CD55-3). GAPDH pSilencer construct was used as transfection control, and pSilencer
containing Scrambled siRNA was used as siRNA control. Increasing cycles (15, 20, and 25 cycles) were used to assess CD55 mRNA expression, whereas -actin
analysiswas usedas control for PCRamplification. (B) CD55protein expressionwas visualized byWestern blot analysis in theGAPDH,Scrambled, andCD55-3 siRNA
PC-3Luc cells. (C) The effect of CD55 knockdown expression on PC-3 cell sensitivity to complement lysis was determined. (D) Proliferation rates of PC-3Luc cells were
assessed over a 48-hour period using WST-1 proliferation assay.
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cells with VEGF, TNFa, TGFb, IL-6, and EGF and demon-
strated that VEGF, TNFa, and EGF induced an increase in
sCD55 being released into the surrounding matrix. The pres-
ence of CD55 in the tumor microenvironment is currently not
understood; however, it may play an important role in pro-
tecting cancer cells as they seed a metastatic site and pro-
gress to a more aggressive phenotype.
In this present study, we demonstrate for the first time that
inhibition of CD55 using siRNA-mediated knockdown ex-
pression resulted in a 76% decrease in overall tumor burden
after 45 days in a bioluminescent mouse model of metastasis
(Figure 5B). There was no apparent effect of the number of
metastatic lesions or the initial rate of PC-3Luc cell seeding
between the CD55 knockdown PC-3Luc cell line and the
Scrambled negative control (data not shown). These data
indicate a decrease in the ability of PC-3Luc cells deficient
in CD55 to successfully grow at a metastatic site and sug-
gest an important role for CD55 in prostate cancer growth
and survival.
The complement immune system is activated during var-
ious malignancies, including colorectal and prostate cancers
[14,27–29]. Tumor cells have been shown to increase com-
plement activation, resulting in the deposition of C3 and C4
in breast cancer and papillary thyroid carcinoma [28,30,31]. In
Figure 5. Downregulation of CD55 reduces total tumor burden in vivo. PC-3Luc cells containing either Scrambled siRNA or CD55-3 siRNA constructs were
introduced to male SCID mice by intracardiac injection, and tumor volume was monitored over 45 days by bioluminescent imaging (A). Day 45 total tumor burden
was measured by ROI quantification of photons-per-second emission from mice injected intraperitoneally with luciferin (B). Histologic analysis of tibial lesions by
hematoxylin and eosin staining with 25 objective (C and F) and 400 objective (D and G). Arrows indicate the presence of tumor cells in representative sections.
Immunohistochemical analysis with anti-luciferase antibodies (E and H) was used to confirm the PC-3 Luc cell origin of tumors.
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response to elevated complement activity, cancer cells have
developed a mechanism of protection for survival by upregu-
latingmCRPexpression [32].Several studieshaveshowncer-
tain malignancies presenting varying complement activities
and tumor cells having varying resistance to complement-
mediated lysis [11,32,33]. Varying resistance to the com-
plement system is most likely due to differentially expressed
mCRPs within a tumor and between cancers. Expression of
mCRPs has been demonstrated in breast cancer, gastric
cancer, colorectal cancer, and leukemia and is variable be-
tween cancer and within tumors [13,29,31,33–35]. CD55,
specifically, has been implicated in tumorigenesis in colorectal
cancer. Reports have demonstrated the overexpression of
CD55 in colorectal cancer specimens compared to normal
results from patients’ histology samples and LS174T cells (a
colon carcinoma cell line) [36].
Tumor cells have developed several escape mechanisms
utilized to promote tumorigenesis andmetastasis. Tumor cells
are known todownregulate tumorantigens [37], expressmole-
cules that inhibit T-cell viability and expansion [B7-H (PDL1
andPDL2) and indoleamine2,3-dioxygenase] [38–40], and to
develop resistance to NK, CD8+ T-cell granzymes, and per-
forin [41,42]. In this study, we present data demonstrating that
the inhibition of complement-mediated lysis by the upregula-
tion of CD55 protects PCa cells and promotes prostate cancer
tumorigenesis andmetastasis. Further studies are required to
further understand the role of CD55 in tumor cell biology and
its potential for targeted therapy; however, evidence pre-
sented here implicates CD55 as an important mediator of
prostate cancer cell survival and tumor growth.
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